ロード中...
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7973794/ https://ncbi.nlm.nih.gov/pubmed/33737682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85948-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|